Introduction {#sec1-1759091417726607}
============

The molecular signaling events that regulate neuroprotection and excitotoxic cell death have been an area of intensive investigation for many years. Beyond the well-established roles of a subset of signaling pathways that underlie either neuroprotection (e.g., the Nrf2-Antioxidant Response Element signaling pathway) or cell death (e.g., the intrinsic apoptotic pathway), numerous cell signaling events and gene networks have the capacity to confer both protection *and* to enhance vulnerability to potentially excitotoxic insults ([@bibr50-1759091417726607]; [@bibr11-1759091417726607]; Culmsee and Landshamer, [@bibr19-1759091417726607]; [@bibr63-1759091417726607]). Consistent with this idea, the extracellular signal-regulated kinase (ERK)/MAPK pathway has been shown to function as both a regulator of neuroprotective and cell death signaling pathways (reviewed in [@bibr34-1759091417726607]; [@bibr76-1759091417726607]; [@bibr10-1759091417726607]; [@bibr49-1759091417726607]; [@bibr67-1759091417726607]). Along these lines, a large number of *in vitro* and *in vivo* studies have shown that the abrogation of ERK/MAPK signaling suppresses neuronal death induced by multiple apoptotic- and necrotic-mediated mechanisms ([@bibr1-1759091417726607]; [@bibr42-1759091417726607]; [@bibr46-1759091417726607]; [@bibr59-1759091417726607]; [@bibr58-1759091417726607]). In contrast with these findings, studies have also shown that the ERK/MAPK pathway facilitates neuronal cell survival (reviewed in [@bibr4-1759091417726607]; [@bibr60-1759091417726607]). For example, ERK/MAPK signaling has been shown to stimulate preconditioning-mediated neuroprotection ([@bibr29-1759091417726607]; [@bibr7-1759091417726607]) and to drive the expression of neuroprotective genes, including BCL-2 and *BDNF* ([@bibr33-1759091417726607]; [@bibr14-1759091417726607]).

These profoundly discordant observations regarding ERK/MAPK signaling and cell viability may be explained by the route of injury, duration of activation, and the subcellular localization of ERK ([@bibr34-1759091417726607]; [@bibr76-1759091417726607]; [@bibr10-1759091417726607]; [@bibr49-1759091417726607]). Here, we chose to further our understanding of the role of MAPK signaling in neuroprotection by focusing on one of its principal effector kinases: *M*itogen- and *S*tress-activated protein *K*inase 1 (MSK1). MSK1 (and its homolog MSK2) is a serine/threonine kinase that is formed by two distinct functional domains: an autoregulatory C-terminal kinase and an N-terminal substrate kinase (reviewed in [@bibr31-1759091417726607]; [@bibr2-1759091417726607]; [@bibr62-1759091417726607]). In addition to its regulation by the ERK/MAPK cascade, MSK1 is downstream of the p38/MAPK pathway ([@bibr22-1759091417726607]; [@bibr51-1759091417726607]).

MSK1 is localized to the cell nucleus and functions as a regulator of chromatin structure and transcription factor activation. For example, MSK1 phosphorylates histone H3 and the transcription factors ATF-1 and CREB ([@bibr74-1759091417726607]; [@bibr66-1759091417726607]; and reviewed in [@bibr2-1759091417726607]; [@bibr71-1759091417726607]; [@bibr62-1759091417726607]). Notably, via its phosphorylation of CREB at Ser133 (and the resulting increase in CRE-mediated gene expression), MSK1 appears to be a key route by which the ERK/MAPK pathway triggers long-term forms of neuronal plasticity. Consistent with this idea, *MSK1*-deficient mice exhibit an array of synaptic and cognitive deficits ([@bibr17-1759091417726607]; [@bibr39-1759091417726607]; Correa et al., 2012). Further, MSK1 regulates progenitor cell proliferation in the subgranular zone of the dentate gyrus ([@bibr40-1759091417726607]), which could also contribute to the cognitive deficits observed in *MSK1* null mice.

As with signaling via the ERK/MAPK pathway (an upstream effector of MSK1), there are divergent findings regarding the role of MSK in cell death signaling, with reports showing that MSK is both protective and can enhance vulnerability to stress stimuli ([@bibr35-1759091417726607]; [@bibr38-1759091417726607]; [@bibr43-1759091417726607]). Here, we furthered this line of inquiry and provide data showing that the MSK1 pathway plays an important role in conferring resistance against seizure-evoked cell death.

Materials and Methods {#sec2-1759091417726607}
=====================

Mice {#sec3-1759091417726607}
----

*MSK1^−/−^* mice (also referred to here as *MSK1* null mice) and *MSK1^+/+^* (also referred to here as MSK1 WT mice) were provided by Dr. J. Simon C. Arthur (University of Dundee, Dundee, Scotland) and bred at the Ohio State University. MSK1^−/−^ and MSK1 WT mice were genotyped via PCR profiling of DNA isolated from tail biopsies: The PCR cycling conditions and primers are described by [@bibr74-1759091417726607]. The *MSK1^−/−^* deletion line was bred into a C57Bl/6 line for \>10 generations. For the experiments shown in [Figures 2(d)](#fig2-1759091417726607){ref-type="fig"} and [3](#fig3-1759091417726607){ref-type="fig"}[](#fig4-1759091417726607){ref-type="fig"}[](#fig5-1759091417726607){ref-type="fig"}[](#fig6-1759091417726607){ref-type="fig"} to [7](#fig7-1759091417726607){ref-type="fig"}, which constitute the cell death profiling and array assays, experimental mice were derived from *MSK1^+/−^* breeder cages; hence, *MSK1^+/+^* (WT) and MSK1*^−^*^/^*^−^* littermates with the same genetic background were used. Standard C57Bl/6 mice, originally acquired from Jackson Labs, were used for the MSK1, pMSK1, and pERK1/2 expression profiling assays ([Figures 1](#fig1-1759091417726607){ref-type="fig"} and [2(a)](#fig2-1759091417726607){ref-type="fig"}, ([b](#fig2-1759091417726607){ref-type="fig"}), ([c](#fig2-1759091417726607){ref-type="fig"}), ([e](#fig2-1759091417726607){ref-type="fig"}), and ([f](#fig2-1759091417726607){ref-type="fig"})). For all studies, adult, 6- to 14-week-old mice were used. Animals were entrained to a standard 12:12 light/dark cycle and were allowed *ad libitum* access to water and food. The studies reported here were conducted in compliance with the Ohio State University Institutional Animal Care and Use Committee guidelines. Figure 1.MSK1 expression in the hippocampus. (a) Immunohistochemical labeling revealed MSK1 expression within the principal hippocampal cell layers (CA1, CA3, and GCL). Bar: 400 µm (low magnification image). Bar: 50 µm (high magnification image). (b) Immunofluorescent double labeling for MSK1 and NeuN; colocalized expression was observed in the CA1, CA3, and GCL. CA1 panel: Arrows denote a subset of cells with high MSK1 expression. CA3 panel: Arrowheads denote nonneuronal cells with high MSK1 expression. SR: stratum radiatum. GCL panel: Boxes denote hilar interneurons with limited MSK1 expression. (c) PCR-based genotyping of the targeted (−/−) and WT (+/+) *MSK1* allele; tail biopsies were processed from two animals from each genotype. (d) Immunohistochemical labeling (top panel) and Western blotting (bottom panel) were used to confirm the loss of MSK1 protein in *MSK1* null mice. Figure 2.Seizure activity stimulates MSK activation. WT mice were injected with vehicle (control) or with pilocarpine and sacrificed 15 to 30 min after the induction of Stage 5 seizure activity. (a) Immunohistochemical labeling revealed limited MSK phosphorylation in the CA1 and GCL of control mice. (b) Marked phosphorylation in the CA1 and GCL was detected following seizure activity. Boxed regions in the left panels in (a) and (b) are magnified and presented to the right. Bar: 50 µm. (c) Western analysis of hippocampal lysates (from WT mice) were also used to profile MSK phosphorylation (pMSK) following seizure activity: Note that the increased band intensity in lysates isolated from pilocarpine (seizure)-treated animals. As a loading control, the blot was also probed for β-actin expression. Each lane represents lysate from an individual animal. Data are representative of three separate trials. (d) EEG analysis of pilocarpine-evoked SE. Top: representative traces from a WT and *MSK1* null mouse. Recordings are from the start of motor seizure activity and continue to SE. Arrows denote the approximate onset of SE. Bottom: Mean SE-evoked EEG activity amplitude (peak-to-peak: P--P) for WT and *MSK1* null mice. Significant P--P differences were not detected between the genotypes at any of the time points. Data were averaged from four animals from each genotype. Immunohistochemical labeling for ERK1/2 activation in WT (e) and *MSK1* null mice (f). Animals were sacrificed 30 min after vehicle injection (top panels) or ∼15 min after pilocarpine-evoked Stage 5 seizure activity (bottom panels). Note the marked increase in seizure-evoked hippocampal ERK1/2 activation in both WT and *MSK1* null mice. Data are representative of triplicate determinations. Figure 3.SE-evoked cell death phenotype in *MSK1* null mice. (a) *MSK1* null mice (MSK1^−/−^) and WT (MSK1^+/+^) mice were challenged with pilocarpine-evoked SE (or saline vehicle), sacrificed 3 days later, and coronal sections through the hippocampus were labeled with FJB. In WT mice, SE evoked a stereotypical pattern of cell death in the hilus, CA3, and CA1 cell layers. Interestingly, in *MSK1* null animals, there was a marked, relative, increase in cell death within the CA3 and CA1 cell layers. ((b)--(d)) Quantitative analysis of FJB-positive cells in the CA1 (b), CA3 (c), and hilus (d). \**p* \< .01. Of note, in control mice (saline injection), cell death was not detected in either *MSK1* null or WT mice.

Pilocarpine-Induced SE {#sec4-1759091417726607}
----------------------

The pilocarpine model was used to induce status epilepticus (SE) ([@bibr20-1759091417726607]). Initially, mice received an *i*ntra*p*eritoneal (IP) injection of atropine methyl nitrate (1.3 mg/kg in saline, Sigma, St Louis, MO). Thirty minutes later, mice were IP injected with pilocarpine (310 mg/kg, Sigma) diluted in physiological saline to evoke SE. The Racine grading scale ([@bibr61-1759091417726607]) was used to assess seizure magnitude and SE onset. SE was defined as multiple Stage 5 motor seizures (tonic-clonic seizures observed in all four limbs, which resulted in a loss of balance) that persisted for ≥3 h. SE was not terminated with diazepam.

Immunohistochemistry {#sec5-1759091417726607}
--------------------

For all histological analysis, mice were sedated using ketamine/xylazine anesthetic (ketamine: 120 mg/kg of body weight and xylazine: 24 mg/kg body weight), and tissue was fixed using transcardial perfusion with paraformaldehyde (4%) diluted in phosphate-buffered saline (PBS). Isolated whole brains were then postfixed in paraformaldehyde (4% for 4 h at 4℃) followed by cyroprotection using 30% sucrose. Stereotaxic coordinates from anterior to posterior from bregma: −1.40 to −2.20 mm were used to cut 40-µm coronal sections through the dorsal hippocampus.

Immunolabeling commenced with a series of wash steps in PBS, followed by incubation in PBS with 0.3% hydrogen peroxide. Next, the tissue was blocked (2 h at room temperature) using 10% normal goat serum or 3% normal horse serum diluted in PBS with 1% Triton X-100 (PBST). Sections were then immunolabeled (overnight at 4℃) using rabbit polyclonal anti-pMSK1 (1:1,000 dilution, Cell Signaling, Danvers, MA; catalog number: 9594) or rabbit polyclonal anti-pERK1/2 (1:1,000 dilution, Cell Signaling, catalog number: 9101). Next, the tissue was processed using the ABC labeling method and then incubated with horseradish peroxidase (HRP) avidin (Vector Labs; San Carlos, CA). Visualization of the immunolabeling was achieved by incubating the tissue with nickel-intensified diaminobenzidine substrate (Vector Labs) for HRP. Tissue was then mounted on gelatin-subbed slides, cleared with xylenes and coverslipped using Permount (Fisher Scientific). Photomicrographs were acquired using a Leica DM IRB microscope (Nussloch, Germany).

Cresyl Violet Staining {#sec6-1759091417726607}
----------------------

Mice were transcardially perfused, as described earlier, and 40-µm-thick sections through the hippocampus were mounted on gelatin-coated slides, dehydrated in alcohol, and stained in cresyl violet solution (0.3%). Next, the sections were destained (0.1% glacial acetic acid in 95% ethanol), cleared with xylenes, and finally coverslipped with Permount. Photomicrographs were acquired as described earlier.

Fluoro-Jade B {#sec7-1759091417726607}
-------------

Fluoro-Jade B (FJB) labeling was performed using the methods described in [@bibr16-1759091417726607]. Image collection was performed using a Zeiss 510 confocal microscope.

Cell Quantitation {#sec8-1759091417726607}
-----------------

Photomicrographs of cresyl violet and FJB-labeled cells were acquired at 40× magnification, and digital images were captured and data quantified using MetaMorph software (Universal Imaging, West Chester, PA). Quantitation was performed on the CA1, CA3, and hilar regions of the hippocampus. The hilus was defined as the region between the lower and upper granule cell layer (GCL) blades. The total number of FJB- and cresyl violet-positive cells in each of four dorsal hippocampal sections were counted. Each section was separated by a 200-µm interval (stereotaxic coordinate AP, approximately −1.40 to −2.20 mm). Cell counts were averaged for each animal and then used to generate group mean ± SEM values for each condition. For the 3-day post-SE data sets, six to eight mice were used for each group; for the 6-week time points, four to six animals were used for each group. Data are reported as the mean ± the SEM for each condition. Mean values were statistically analyzed between cell layers (e.g., control vs. experimental) using the Student's *t* test, and a *p* \< .05 was considered significant.

Immunofluorescent Labeling {#sec9-1759091417726607}
--------------------------

Sections were washed with PBS and then blocked (2 h room temperature) with 10% normal goat serum in PBST. Next, sections were incubated overnight (at 4℃) with a rabbit polyclonal total MSK1 antibody (1:500 dilution, Cell Signaling, catalog number: 3489) and with a mouse monoclonal anti-NeuN antibody (1:1,000 dilution, Millipore, Billerica, MA; catalog code: MAB377). Tissue was then washed 5× in PBST and incubated for 2 h (at 22℃) with goat polyclonal Alexa 488- and donkey polyclonal Alexa 594- (1:1,000 dilution, Invitrogen, Carlsbad, CA) conjugated secondary antibodies. Next, sections were washed, and DNA was labeled with Hoechst (1 µg/ml: Cell Signaling). Finally, tissue was mounted with Cytoseal (Richard-Allan Scientific, Kalamazoo, MI), and images were acquired with a Leica SP8 confocal microscope.

Western Blotting {#sec10-1759091417726607}
----------------

Animals were sacrificed as described earlier, and hippocampi were dissected from whole brains. Tissue was lysed in radioimmunoprecipitation assay buffer, and then protein extracts (5 µg/µL) were loaded onto 10% SDS-PAGE gels and electrophoresed and then transblotted onto polyvinylidene difluoride membranes (Immobilon-P; Millipore) using standard methodologies. Next, membranes were blocked with 10% milk in tris-buffered saline containing 0.1% Triton-X-100 (TBST: 1 hr) and then incubated overnight with the noted MSK1 (1:500 dilution) or pMSK (1:1,000, dilution) antibodies. After washing, membranes were treated (1 hr at room temperature) with an anti-rabbit IgG HRP-conjugated antibody (1:2,000 dilution, PerkinElmer Life Sciences), and the HRP signal was detected using the Renaissance bioluminescent detection system (New England Nuclear). Blots were then stripped and probed using a mouse monoclonal β-actin antibody (1:1,000, PhosphoSolutions Catalog code: 125-ACT), and the signal was detected using the noted HRP labeling and visualization steps.

RNA isolation and microarray analyses {#sec11-1759091417726607}
-------------------------------------

Mice were sacrificed, and brains were isolated as described earlier. Bilateral hippocampal tissue was removed, and total RNA was purified using TRIzol (Invitrogen) following the manufacturer's protocol. RNA quantity and quality was assayed using an Agilent 2100 Bioanalyzer (Agilent Technologies), and the RNA from three animals per genotype (WT and *MSK1* null) was prepared for array profiling using the GeneChip one-cycle target labeling kit (Affymetrix). Biotinylated cRNA was profiled using the GeneChip 430 2.0 Mouse Genome Array, running one array per mouse: (e.g., three animals/arrays per genotype). cRNA preparation, microarray hybridization, and profiling were performed at the Ohio State University Microarray Core Facility. Raw data (.cel files) were processed using dChip software (<http://www.hsph.harvard.edu/cli/complab/dchip/>). The resulting data sets were filtered to identify genes that were significantly altered by the deletion of MSK1; a 1.25-fold change in expression with a *p* value of ≤ .05 was considered significant. Subsequently, Matlab R2016a (MathWorks) was used to generate the hierarchical clustering map based on the expression values of significantly altered genes. Finally, gene functional classification and clustering were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID), with significant enriched annotation terms set to *p* values of ≤ .05. Graphical representation of the analysis results was completed using the Cytoscape software Enrichment Map plug-in. Microarray data are available from the Gene Expression Omnibus website (<http://www.ncbi.nlm.nih.gov/geo>), under accession number: GSE98751.

Neuronal Toxicity Assays {#sec12-1759091417726607}
------------------------

Neuronal cell death after an N-methyl-D-aspartate (NMDA) challenge in primary hippocampal neurons from *MSK1* null and WT mice was assessed as described in [@bibr12-1759091417726607]. Briefly, neurons were isolated from the hippocampus of postnatal day 1 mice, dissociated with trypsin, and plated on polylysine-coated 12-mm glass coverslips in a 24-well plate. The cells were maintained in Neurobasal media supplemented with 2% B27, 1% penicillin/streptomycin, and 0.25 mM glutamine (all culture media were from Gibco) for 10 days. NMDA (50 µM) with 2 µM glycine (or control solution) was added to the cultures for 20 min, and the cell culture media was collected at 4 h and 8 h for the measurement of lactate dehydrogenase (LDH) release as a measure of loss of membrane integrity (measured as described in [@bibr12-1759091417726607]). Brightfield images of the cells were also acquired as a record of cell health/death. Finally, at 8 h after NMDA/glycine treatment, cultures were fixed with 4% paraformaldehyde for 30 min at room temperature, permeabilized with 0.4% Triton X-100 for 10 min at 37℃, and blocked with 10% bovine serum albumin for 60 min at 37℃. The cultures were then incubated overnight (at 4℃) in monoclonal MAP2 antibody (1:500 dilution, HM-2 clone, Sigma, St. Louis, MO) in PBS containing 3% bovine serum albumin/0.4% Triton X-100. After washing (3×) with PBS, the cells were incubated 60 min (at 37℃) with an Alexa 488-conjugated antibody against mouse IgG (1:1000, Molecular Probes, Eugene, OR). Finally, the cells were stained with Hoechst (as described above), mounted on glass slides with PBS/glycerol (1:3), and sealed with nail polish. Fluorescence images were captured using a CoolSnap HQ digital camera (Roper Scientific, Tucson, AZ) connected to a Nikon TE2000S epifluorescence microscope (Nikon Instruments, Melville, NY). FITC excitation/emission filters were used to visualize MAP2 while DAPI filters were used for Hoechst 33258. Data were analyzed using MetaMorph software. Mean values were statistically analyzed between control and experimental conditions and between cell phenotypes using the Student's *t* test, and a *p* \< .05 was considered significant.

Intracellular Calcium Measurement {#sec13-1759091417726607}
---------------------------------

Hippocampal neurons cultured on 12 mm coverslips were loaded with 5 µM Fura-2 AM (Molecular Probes) for 45 min at room temperature in a HEPES-based buffer (HBSS) containing the following (in mM): 137 NaCl, 5.6 glucose, 20 HEPES, 5 KCl, 0.6 Na~2~HPO~4~, 0.6 KH~2~PO~4~, 10 NaHCO~3~, 0.9 MgSO~4~, and 1.4 CaCl~2~, pH 7.4. Coverslips were then placed in a laminar flow chamber and mounted on the stage of a Nikon TE2000S epifluorescence microscope. Single-cell ratiometric (alternating 340 nm/380 nm excitation wavelengths and 510 nm emission wavelength) fluorescence traces were acquired at 10-s intervals using MetaFluor software controlling a CoolSnap digital camera. Neurons were identified by morphology as assessed from bright-field images. Results are presented as background subtracted 340 nm/380 nm ratios. All NMDA-containing solutions were made in HBSS and contained 0.5 µM tetrodotoxin. NMDA solutions included 1 µM glycine and omitted MgSO~4~. Mean-evoked response values were statistically analyzed between cell phenotypes using the Student's *t* test, and a *p* \< .05 was considered significant.

Electroencephalogram Recording {#sec14-1759091417726607}
------------------------------

Electroencephalogram (EEG) electrode placement, recordings, and analysis were performed as described in our previous study ([@bibr45-1759091417726607]). Briefly, animals were surgically implanted with bipolar recording electrodes (Plastics One, Roanoke, VA): one within hippocampal area CA1 (anterior −1.8 mm from bregma; lateral 1.1 mm; and dorsoventral 1.2 mm) and the other within the cortex (anterior −2.8 mm from bregma; lateral 1.1 mm; and dorsoventral 1.2 mm). Animals were then allowed to recover from the electrode implantation procedure for 10 days prior to the initiation of the SE paradigm (described earlier). EEG recording was started 10 min prior to pilocarpine injection, and data were recorded for approximately 120 min post-SE onset. The MP150 data acquisition system (Biopac Systems, Santa Barbara, CA) was used to record polysomnographic signals, and data analysis was performed using Acknowledge 3.9.0 software (Biopac Systems). EEG data were analyzed at 10-min intervals, and the average peak-to-peak values were generated from 20-s EEG traces. Four WT and 4 *MSK1* null mice were profiled for this study. Mean peak-to-peak response values were statistically analyzed between mouse lines using the Student's *t* test, and a *p* \< .05 was considered significant.

Results {#sec15-1759091417726607}
=======

MSK1 Expression and Activation in the Hippocampus {#sec16-1759091417726607}
-------------------------------------------------

As a starting point for our analysis, we used immunohistochemical labeling to examine MSK1 expression in the hippocampus. Consistent with prior reports ([@bibr15-1759091417726607]; [@bibr39-1759091417726607]), MSK1 was detected in all major neuronal cell layers, including the CA1, CA3, and the GCL ([Figure 1(a)](#fig1-1759091417726607){ref-type="fig"}). MSK1 expression was low in the CA1 relative to expression in the CA3 and the GCL. Double immunofluorescent labeling for MSK1 and for the neuronal-specific marker NeuN ([Figure 1(b)](#fig1-1759091417726607){ref-type="fig"}) confirmed the neuronal expression of MSK1, and double labeling with the DNA stain Hoechst showed that MSK1 was concentrated in cellular nuclei. Interestingly, although the vast majority of CA1 neurons exhibited a low level of MSK1, there was a subset of neurons that expressed high levels of the kinase ([Figure 1(b)](#fig1-1759091417726607){ref-type="fig"}: CA1 panel; arrows denote high-expressing cells). In the hilus, limited MSK1 expression was detected in NeuN-positive neurons, indicating low-level MSK1 expression in interneuron cell populations ([Figure 1(b)](#fig1-1759091417726607){ref-type="fig"}: GCL panel; boxed regions denote hilar neurons with limited MSK1 expression). MSK1 was also detected in nonneuronal cells, as noted in the CA3 panel of [Figure 1(b)](#fig1-1759091417726607){ref-type="fig"} (arrowheads denote MSK1-positive, NeuN-negative, cells within the stratum radiatum). Finally, a *MSK1* null mouse line ([Figure 1(c)](#fig1-1759091417726607){ref-type="fig"}) was used to test the specificity of the MSK1 immunolabeling; importantly, MSK1-like immunoreactivity (using both immunohistochemistry and Western blotting) was not detected in tissue from the *MSK1* null mouse line ([Figure 1(d)](#fig1-1759091417726607){ref-type="fig"}).

Next, we examined MSK1 activation resulting from pilocarpine-evoked (310 mg/kg: IP injection) SE. Of note, the SE model system has been widely used to examine mechanisms of excitotoxic and neuroprotective response processes and mechanisms underlying epileptogenesis ([@bibr73-1759091417726607]; [@bibr20-1759091417726607]; [@bibr21-1759091417726607]). Initially, mice were sacrificed 15 to 30 min after the induction of Stage 5 seizure activity, and hippocampal tissue was probed with an antibody against the Ser-360 phosphorylated form of MSK (pMSK), a marker of MSK activation ([@bibr51-1759091417726607]). Of note, this antibody does not distinguish between MSK1 and MSK2. In control, vehicle-injected mice, very limited pMSK was detected within the principal cell layers of the hippocampus, although high background staining was observed in the hippocampal subfields and fiber tracks ([Figure 2(a)](#fig2-1759091417726607){ref-type="fig"}). In contrast, SE evoked marked MSK phosphorylation in the major hippocampal cell layers (CA1, GCL: [Figure 2(b)](#fig2-1759091417726607){ref-type="fig"}) and in the CA3 (data not shown); this expression pattern is consistent with the nuclear expression pattern that was observed for total MSK1 expression (see [Figure 1(b)](#fig1-1759091417726607){ref-type="fig"}). Immunohistochemistry was complemented with pMSK Western analysis of hippocampal lysates (probed with the same pMSK antibody used for immunolabeling). Relative to control tissue, SE trigged an increase in the expression of an ∼90 kDa band, consistent with the molecular weight of MSK1 (and MSK2). As a control, the blot was also probed for total β-actin expression. Together, these data reveal that MSK1 is expressed in hippocampal neurons, and that its activation is coupled to seizure activity.

MSK1 Confers Neuroprotection Against Excitotoxic Cell Death {#sec17-1759091417726607}
-----------------------------------------------------------

Next, we examined the potential role of MSK1 signaling in the excitotoxic response induced by SE. This line of inquiry was predicated on a large body of work showing that the MSK1 effector pathways (ERK/MAPK and P38/MAPK) affect cell viability. To address this question, we used a *MSK1* null mouse line (MSK1^−/−^: [Figure 1(c) and (d)](#fig1-1759091417726607){ref-type="fig"}), in which the *MSK1* allele was selectively deleted using homologous recombination ([@bibr3-1759091417726607]). In our two prior studies ([@bibr15-1759091417726607]; [@bibr39-1759091417726607]), we provided a detailed description of the line, noting that *MSK1* null mice are fertile, and that no health issues were detected. Further, compared with the WT mice, gross morphological differences in the hippocampus were not detected in *MSK1* null mice. Of note, degeneration has been described within the striatum of aged (9 months) *MSK1* null mice ([@bibr48-1759091417726607]). However, within the 6- to 14-week age range used in our study, hippocampal neurodegeneration was not detected (described later). Further, with respect to the SE paradigm, WT mice and *MSK1* null mice showed similar seizure onset times following pilocarpine injection, and there were no marked differences in the motor manifestations, and the progression of seizure severity. Using the Racine scale ([@bibr61-1759091417726607]) both lines exhibited the stepwise progression from Stage 1 to Stage 5 seizure activity. A subset of *MSK1* null (35%) and WT (40%) mice transitioned to SE; SE-evoked mortality rates between the two lines were similar, with MSK1 nulls exhibiting a slightly higher rate than WT mice (45% vs. 40%, respectively, *N* = 20/per genotype). EEG recording revealed high-amplitude electrical discharges, and peak-to-peak analysis detected a similar level of SE-evoked electrical activity in WT and *MSK1* null mice ([Figure 2(d)](#fig2-1759091417726607){ref-type="fig"}). Finally, immunohistochemical labeling for the activated, dual phosphorylated, form of ERK1/2 was used to test whether seizure activity drives an expected increase in ERK/MAPK pathway activation. In both WT ([Figure 2(e)](#fig2-1759091417726607){ref-type="fig"}) and *MSK1* null ([Figure 2(f)](#fig2-1759091417726607){ref-type="fig"}) lines, 15 min of Stage 5 seizure activity led to a robust, hippocampal wide, increase in ERK phosphorylation. Together, these data indicate that *MSK1* null and WT mice exhibit similar sensitivities and response properties to pilocarpine. Further, when combined with the data described later, these results indicate that the *MSK1* null cell death phenotype is likely not the result of an enhanced sensitivity to pilocarpine, but rather can be ascribed to an elevated cellular-level vulnerability to the excitatory insult.

To analyze the potential role of MSK1 in SE-evoked excitotoxic cell death, WT (referred to as MSK1^+/+^ mice in the figure) and MSK1 null mice were sacrificed 3 days after pilocarpine-evoked SE, and hippocampal tissue was examined for cell death via FJB labeling. Initially, under control conditions (no pilocarpine injection), FJB-positive cells were not detected in the WT or *MSK1* null mice ([Figure 3(a)--(d)](#fig3-1759091417726607){ref-type="fig"}). In WT mice, SE led to cell death within the CA1, CA3, and hilar region, whereas limited cell death was detected in the GCL ([Figure 3(a)](#fig3-1759091417726607){ref-type="fig"}). Interestingly, compared to WT mice, *MSK1* null mice exhibited a significant increase in SE-evoked cell death within the CA1 and CA3 cell layers ([Figure 3(a)--(c)](#fig3-1759091417726607){ref-type="fig"}). However, within the hilus, similar high levels of cell death were detected in WT and *MSK1* null mice ([Figure 3(a) and (d)](#fig3-1759091417726607){ref-type="fig"}).

Nissl staining was used to complement the 3-day post-SE FJB labeling and extend the analysis of cell death out to 6-week post-SE ([Figure 4](#fig4-1759091417726607){ref-type="fig"})---a time point when animals exhibit spontaneous seizure activity. Nissl staining of tissue at the 3-day post-SE time point confirmed the findings using FJB: A significant increase in CA1 and CA3 cell death in *MSK1* null mice relative to WT mice ([Figure 4(a) and (c)](#fig4-1759091417726607){ref-type="fig"}). Interestingly, marked degeneration of the GCL was observed in 1 *MSK1* null mice ([Figure 4(a)](#fig4-1759091417726607){ref-type="fig"}, bottom panel), which represents ∼6% of the *MSK1* null mice profiled (*n* = 18 in total); GCL degeneration was not detected in WT mice (*n* = 20 in total). Representative data and quantitative analysis for the 6-week time point revealed a significantly higher level of cell death in the *MSK1* null line ([Figure 4(b)--(d)](#fig4-1759091417726607){ref-type="fig"}). Together, these data indicate that MSK1 confers potent neuroprotection against SE-evoked excitotoxicity. Further, these data indicate that the abrogation of MSK1 signaling does not affect cell viability under normal, nonpathophysiological conditions. Here, it is worth noting that a prior study reported that MSK1 enhances neuronal cell death ([@bibr35-1759091417726607]). Clearly, this result is inconsistent with our work reported here. Possible explanations for these divergent results could be related to either the experimental methods used to stimulate an excitotoxic challenge or the different experimental methods used to disrupt MSK1 signaling (the work of Hughes et al. largely utilized small molecular inhibitor-based approaches). As noted in the Introduction section, signaling via the ERK/MAPK pathway can confer neuroprotection or facilitate neuronal cell death, depending on the stimulus conditions: Given that MSK1 is downstream of ERK/MAPK, it may also play a similar, context-specific, role. Figure 4.Cell death at 3 days and 6 weeks post-SE. Nissl staining was used to profile SE-induced cell death in WT (MSK1^+/+^) and *MSK1* null (MSK1^−/−^) mice. (a) Consistent with the cell death profile generated using FJB labeling ([Figure 3](#fig3-1759091417726607){ref-type="fig"}), an elevated level of cell death was detected in the CA1 and CA3 cell layers of *MSK1* null mice at the 3-day post-SE time point. Interestingly, marked cell death was occasionally observed in the GCL layer of *MSK1* null mice. (b) Representative Nissl staining at 6 weeks post-SE in WT and *MSK1* null mice; note the marked cell death within the CA1 and CA3 cell layers of *MSK1* null mouse Quantitation of cell density in the CA1 and CA3 (c) and the hilar (d) cell layers at both the 3-day and 6-week post-SE time points. \**p* \< .01.

The increase in evoked cell death observed in *MSK1* null mice could be due to a number of factors, including an increase in SE-evoked excitatory drive and a decrease in cellular neuroprotection. To address these two possibilities, we prepared primary hippocampal neuronal cultures from postnatal day 1 *MSK1* null and WT mice and tested their response profiles to NMDA stimulation. We initially tested NMDA-induced cell death in neurons cultured for 10 days using the LDH assay. For these studies, neurons were stimulated (20 min) with 50 µM NMDA (supplemented with 2-µM glycine), and LDH release was examined 4 h and 8 h later. Relative to WT neurons, NMDA-evoked cell death was markedly increased in *MSK1* null cultures at both time points ([Figure 5(a)](#fig5-1759091417726607){ref-type="fig"}). Photomicrographs of *MSK1* null cultures at 8 h post-NMDA stimulation revealed a large number of shrunken cells with fragmented processes; in contrast, the cellular morphology of WT neurons was largely intact, with only a relatively small number of cells exhibiting signs of necrosis ([Figure 5(b)](#fig5-1759091417726607){ref-type="fig"}). To confirm that cell death occurred in neurons, cultures were also labeled for the neuronal-specific cytoskeletal protein MAP2, which has been used to profile excitotoxic cell death in culture ([@bibr12-1759091417726607]). Consistent with the LDH data set, *MSK1* null cultures treated with NMDA showed a reduction in MAP2 labeling relative to the control *MSK1* null cultures (mock stimulation) and compared to WT cultures treated with NMDA ([Figure 5(c)](#fig5-1759091417726607){ref-type="fig"}). Together, these data indicate that MSK1 contributes to cell-autonomous neuroprotective response mechanisms. Figure 5.NMDA-evoked cell death in cultured hippocampal neurons. (a) Primary hippocampal neuronal cultures of *MSK1*^−/−^ null and MSK1 WT (MSK1^+/+^) tissue were maintained for 10 days and then stimulated with NMDA (50 µM with 2 µM glycine added: 20 min), and LDH release was profiled 4 h and 8 h later. Relative to no stimulation, NMDA evoked a modest increase in LDH release in WT neurons. In contrast, marked cell death was detected in MSK1 null neurons. \**p* \< .05 relative to the control, no stimulation, condition; \*\**p* \< .01 relative to the control, no stimulation, condition; \#*p* \< .01 comparing LDH release between the *MSK1* null and WT cultures for each time point. Mean data points were generated from quadruplicate determinations. (b) Representative images of cultured neurons under control conditions (no stimulation) and 8 h after NMDA stimulation. For the NMDA-treated condition, note the relatively large number of *MSK1* null neurons with condensed cell bodies and fragmented processes. (c) Cell viability following NMDA receptor stimulation was also assayed via MAP2 immunolabeling and nuclear staining with Hoechst. Again, note the relative increase in the number of condensed nuclei and the loss of MAP2 labeling in *MSK1* null neurons at 8 h after NMDA treatment.

To extend this line of work, we also examined NMDA-evoked calcium responses of *MSK1* null neurons. For these studies, neurons were cultured for 10 days, loaded with the calcium-sensitive fluorophore Fura-2, and the response profiles of individual neurons were monitored following brief (∼30 s) treatments with NMDA (10--100 µM). Surprisingly, the peak-evoked responses to NMDA were significantly lower in the *MSK1* null neurons than in WT neurons ([Figure 6(a)](#fig6-1759091417726607){ref-type="fig"} and ([b](#fig6-1759091417726607){ref-type="fig"})). Near the end of the experiment ([Figure 6(a)](#fig6-1759091417726607){ref-type="fig"}), neurons were exposed to 100 µM NMDA for 5 min; this long stimulus paradigm was used to assess whether the response profiles to chronically elevated Ca^2+^ levels were affected by MSK1 deletion. Compared to the WT cells, *MSK1* null neurons exhibited a significantly reduced average response profile to the chronic Ca^2+^ load ([Figure 6(c)](#fig6-1759091417726607){ref-type="fig"}). Of note, basal calcium levels were significantly higher in MSK1 null neurons compared to WT neurons ([Figure 6(d)](#fig6-1759091417726607){ref-type="fig"}). Collectively, the cellular level analysis presented here indicates that the disruption of MSK1 signaling reduces excitatory drive, while increasing vulnerability to potentially excitotoxic stimuli. Figure 6.Evoked Ca^2+^ influx is reduced in *MSK1* null neurons. (a) Primary neuronal cultures were maintained for 10 days, loaded with Fura-2, and evoked Ca^2+^ influx was profiled following sequential administrations of NMDA (10, 30, and 100 µM: 30 s each; followed by 100 µM for 5 min). (b) Data represent the mean and SEM of WT (MSK1^+/+^) cultures and *MSK1*^−/−^ null cultures. (c) Average Ca^2+^ response evoked with 100 µM NMDA exposure for 5 min expressed as the mean area under the curve (AUC) for each genotype. (d) Mean resting Ca^2+^ level recorded at the beginning of the experiment. \**p* \< .05. Data were averaged from 29 neurons from the *MSK1* null cultures and 43 neurons from the MSK1 WT cultures. Figure 7.Hippocampal gene expression profile of *MSK1* null mice. (a) Hierarchical cluster analysis comparing differentially expressed genes between MSK1 WT and *MSK1* null mice. A total of 275 genes showed significant changes (≥1.25-fold) in expression, with 145 genes upregulated and 130 genes downregulated. ((b), Top) DAVID functional annotation chart showing enriched gene ontology categories. Top, Categories are sorted based on the EASE score (*p* \< .05). ((b), Bottom) Functional annotation clustering output from DAVID is represented using the Enrichment Map application from Cytoscape. The Enrichment Score (ES) and the number of genes are specified for each cluster. (c) List of genes corresponding to the DAVID Oxidation Reduction Annotation Cluster. As a confirmation of the effectiveness of the Array profiling, the fold-reduction in *MSK1* expression is noted using red font.

MSK1 Deletion Alters the Hippocampal Transcriptome {#sec18-1759091417726607}
--------------------------------------------------

Finally, the complex nature of the MSK1 cell death phenotype (reduced excitatory drive, elevated excitotoxic response to NMDA, and elevated SE-evoked cell death) led us to explore the contribution of MSK1 to the hippocampal transcriptional profile. To this end, hippocampal RNA was isolated from WT and *MSK1* null mice and profiled via Affymetrix array (all array data are presented in a Supplemental Excel Spreadsheet). Using a 1.25-fold cutoff, and a *p* value of \< .05, our data set revealed that the disruption of MSK1 reduced the expression of 130 genes and increased the expression of 145 genes ([Figure 7(a)](#fig7-1759091417726607){ref-type="fig"} and [Table 1](#table1-1759091417726607){ref-type="table"}). Gene ontology (GO) functional clustering analysis via the Database for Annotation, Visualization and Integrated Discovery (DAVID) revealed that MSK1 deletion had significant effects on the expression of several classes of genes associated with membrane receptor signaling, cytoskeletal organization, and redox chemistry ([Figure 7(b)](#fig7-1759091417726607){ref-type="fig"}). The GO term *Neuronal Apoptosis* exhibited clustering, although significance was just below the *p* \< .05 cutoff ([Figure 7(b)](#fig7-1759091417726607){ref-type="fig"}). Together, these data indicate that MSK1 regulates the expression of a large number of genes that underlie basic cellular biochemistry and neuronal-specific cellular signaling. Table 1.Microarray Significant Results.Probe setGeneAccessionEntrez GeneDescriptionWT-1WT-2WT-7Baseline meanBaseline mean's SEMSK-14MSK-15MSK-9Experiment meanExperiment mean's SEFold change*t* statistic*p* value1431050_atRps6ka5: ribosomal protein S6 kinase, polypeptide 5BE29190073086Mm.39471.1247.85229.11261.03246.249.969.868.495.67.732.76−31.85−23.074.0008891440343_atRps6ka5: ribosomal protein S6 kinase, polypeptide 5BQ17426773086Mm.31856.1433.39363.13431.32409.1123.6518.1323.6725.3222.184.6−18.44−16.063.0028031452907_atGalc: galactosylceramidaseAK01010114420Mm.141399.1438.54447.84455.13447.99.5930.1431.6431.4931.089.41−14.41−31.024.0000061422360_atOlfr672: olfactory receptor 672NM_020292258755Mm.103736.16.767.48.187.591.1212.141.591.381.16−5.51−3.852.0182971429511_at4933402E13Rik: RIKEN cDNA 4933402E13 geneAK01661474437Mm.85792.114.4623.8513.7817.353.415.881.742.393.741.68−4.63−3.574.0391741446525_atMm.217589.1BM198842Mm.217589.110.5911.886.929.892.053.5412.482.191.02−4.51−3.368.044881420251_atMm.177311.1AV172782Mm.177311.114.118.219.810.831.893.042.162.392.560.65−4.23−4.14.0369281444813_atMm.211147.1BB521324Mm.211147.113.4915.0212.4513.821.835.0414.283.31.64−4.19−4.285.0131151430998_atSqrdl: sulfide quinone reductase-like (yeast)BE62628359010Mm.28986.213.4416.589.4713.422.42.016.521.383.232.29−4.15−3.072.0373071460269_atPnmt: Phenylethanolamine-N-methyltransferaseAV38042918948Mm.213024.14.345.76.695.471.0111.791.841.381.04−3.97−2.828.0474811432739_at2900060K15Rik: RIKEN cDNA 2900060K15 geneAV15427173041Mm.158931.13.144.732.843.570.6111.021.061.020.65−3.51−2.852.0465211428038_atGm568: predicted gene 568BC028561230143Mm.34995.110.8915.269.7112.092.046.254.3313.611.84−3.35−3.087.0371741457878_atC430042M11Rik: RIKEN cDNA C430042M11 geneBB415623320021Mm.187012.11314.0114.2813.861.212.378.551.584.22.53−3.3−3.449.043721420393_atNos2: nitric oxide synthase 2, inducibleAF06592118126Mm.2893.128.0322.1916.2622.223.4614.065.816.913.83−3.22−2.969.0417061443153_atTrip11: Thyroid hormone receptor interactor 11BB306866109181Mm.208618.150.2967.5479.1165.858.9521.8224.5818.5521.833.22−3.02−4.626.0278471444388_atMm.183515.1BB020727Mm.183515.17.628.417.688.011.283.13.781.012.651.32−3.02−2.917.0434231457563_atEgfr: epidermal growth factor receptorBB40952213649Mm.209083.116.6814.2711.0814.121.94.34.478.395.751.78−2.45−3.217.0325621452205_x\_atGm6273 /// LOC381765 /// LOC665506 /// Tcrb-J: predicted gene 6273 /// similar to T cell antigen receptor /// similar to T-cell receptor beta-2 chain C region /// T-cell receptor beta, joining regionX6712821580 /// 381765 /// 621968 /// 665506Mm.157012.816.1912.5412.8514.042.246.175.435.785.761.86−2.44−2.844.0485181427717_atCd80: CD80 antigenX6095812519Mm.89474.713.1212.4910.6912.181.375.724.55.235.011.44−2.43−3.606.0227211447355_atAcsl1: acyl-CoA synthetase long-chain family member 1BQ12855214081Mm.220877.118.2914.7117.7217.171.329.017.645.437.321.36−2.35−5.196.0065581432542_at2810474C18Rik: RIKEN cDNA 2810474C18 geneAK01340572785Mm.158882.115.8414.4714.3114.891.454.755.658.846.431.67−2.32−3.829.019291418918_atIgfbp1: insulin-like growth factor binding protein 1NM_00834116006Mm.21300.120.8822.0118.1620.541.958.5910.667.299.121.94−2.25−4.152.0142331446391_atMm.209224.1BB450769Mm.209224.146.0837.5338.5640.363.076.8823.3523.4517.986.06−2.25−3.297.0466541453330_atCcdc88c: coiled-coil domain containing 88CAK00245868339Mm.45291.173.536894.6478.699.0525.4843.1943.4737.068.27−2.12−3.394.0277651425447_atDkk4: dickkopf homolog 4 (Xenopus laevis)BC018400234130Mm.157322.111.7813.8714.113.311.325.669.643.766.331.91−2.1−3.003.0463681427395_a\_atAldh1a3: aldehyde dehydrogenase family 1, subfamily A3BC02666756847Mm.140988.211.5210.49.4310.61.015.462.556.985.191.49−2.04−2.996.047211443483_atXlr5a /// Xlr5b /// Xlr5c: X-linked lymphocyte-regulated 5A /// X-linked lymphocyte-regulated 5B /// X-linked lymphocyte-regulated 5CBM20767227084 /// 574438 /// 627081Mm.139096.121.3120.2316.1119.432.216.878.6813.619.852.41−1.97−2.93.0432071454248_atCib4: calcium and integrin binding family member 4AK00667073259Mm.158977.116.1119.2321.919.132.247.799.0612.469.91.81−1.93−3.199.0349691457121_atObsl1: obscurin-like 1AV27187798733Mm.213076.121.5420.8420.2320.812.110.399.8811.9510.762.16−1.93−3.342.0288071431887_atRbm31y: RNA binding motif 31, Y-linkedAK01705574484Mm.159220.134.6233.6335.8334.561.3913.3622.3618.0717.982.84−1.92−5.237.014671440776_atLimch1: LIM and calponin homology domains 1BB70923477569Mm.208624.111.710.57.9410.211.345.935.84.015.30.97−1.92−2.964.0465411439004_atRps6ka5: ribosomal protein S6 kinase, polypeptide 5BE94699973086Mm.101475.1127.44116.07122.49121.675.2964.5667.6262.1164.787.26−1.88−6.333.0042861432163_at4930567K12Rik: RIKEN cDNA 4930567K12 geneAK01624275845Mm.159601.123.423.6432.6826.53.3118.4811.8211.1814.172.61−1.87−2.925.0459431422343_atOlfr155: olfactory receptor 155NM_01947329845Mm.88841.112.919.4312.0511.481.236.217.714.716.271.23−1.83−2.996.0401011420538_atGprc5d: G protein-coupled receptor, family C, group 5, member DNM_05311893746Mm.49902.113.1213.6815.3513.921.237.6710.035.627.641.72−1.82−2.964.0468911444193_atAdhfe1: alcohol dehydrogenase, iron containing, 1BB17767876187Mm.131262.121.8618.9223.0721.121.4113.6511.7210.3211.581.33−1.82−4.91.0080531459589_atCryl1: crystallin, lambda 1C8593268631Mm.200251.114.3111.8711.4712.550.898.625.376.9970.93−1.79−4.314.0125681437721_atCoro1c: coronin, actin binding protein 1CBB54339823790Mm.200372.420.1117.9817.1818.241.9810.297.7512.1310.261.88−1.78−2.927.0431031430693_atPnpla5: patatin-like phospholipase domain containing 5AV25077075772Mm.159565.152.3849.764348.133.462037.1624.4227.245.77−1.77−3.104.047191431193_atTaf4b: TAF4B RNA polymerase II, TATA box binding protein (TBP)-associated factorAK01213572504Mm.158836.129.8237.1129.632.262.7319.2618.0716.9918.191.84−1.77−4.278.0170461449190_a\_atEntpd4 /// LOC100048085: ectonucleoside triphosphate diphosphohydrolase 4 /// similar to ectonucleoside triphosphate diphosphohydrolase 4NM_026174100048085 /// 67464Mm.20806.11825.031840.452179.941947.89118.911355.91020.69982.161119.68118.27−1.74−4.938.0078271438553_x\_at4930453N24Rik: RIKEN cDNA 4930453N24 geneBB81708767609Mm.105351.1175.4183.43195.83185.196.98105.24108.98106.53106.844.37−1.73−9.51.0015291438177_x\_atEntpd4 /// LOC100048085: ectonucleoside triphosphate diphosphohydrolase 4 /// similar to ectonucleoside triphosphate diphosphohydrolase 4AV255351100048085 /// 67464Mm.20806.31188.251260.971525.791325.53103.56949.11619.41740.27769.2996.15−1.72−3.936.0171921457944_atMm.215864.1BM218086Mm.215864.1111.91150.14112.66124.9513.1479.8676.7552.0472.5711.43−1.72−3.007.0406561432514_at1700066J24Rik: RIKEN cDNA 1700066J24 geneAK00690476992Mm.159820.136.7238.0929.2634.683.0813.8226.2420.5920.33.92−1.71−2.882.0479311457653_atMm.133457.1BB292252Mm.133457.18.436.467.87.690.824.723.955.34.60.53−1.67−3.158.0425991424978_atOdf4: outer dense fiber of sperm tails 4AB074438252868Mm.76826.125.6327.9725.4726.662.0319.2817.0512.316.042.45−1.66−3.338.030421458228_atMm.208324.1BB244358Mm.208324.134.3830.8627.7830.832.515.1121.2620.9618.762.76−1.64−3.238.0321941453999_atUrb1: URB1 ribosome biogenesis 1 homolog (S. cerevisiae)AK017495207932Mm.159647.193.17127.33130.35117.1612.3461.8264.7289.9472.199.19−1.62−2.922.0475471456750_atB230303O12Rik: RIKEN cDNA B230303O12 geneBB308463319739Mm.131992.135.4440.735.9437.612.3718.6726.6624.8123.212.78−1.62−3.938.0178381456166_atEhd2: EH-domain containing 2BB358215259300Mm.138215.136.0233.9738.0436.043.0925.0520.9621.4122.451.79−1.61−3.808.0283741418552_atOpn1sw: opsin 1 (cone pigments), short-wave-sensitive (color blindness, tritan)AF19067012057Mm.56987.126.2425.4522.7324.791.7512.1619.8815.1615.72.56−1.58−2.933.0495631459451_atMm.207852.1BB201499Mm.207852.129.0629.6225.2827.871.6317.5514.1421.3917.72.16−1.57−3.754.0226441454218_at4930405D01Rik: RIKEN cDNA 4930405D01 geneAK01509373795Mm.159062.125.1923.4627.6725.45215.418.1715.7916.412.03−1.55−3.175.0337121460064_atBC028789: cDNA sequence BC028789BM237812407802Mm.103545.1178.74142.83147.9715611.6793.72107.19100.39100.785.59−1.55−4.266.0257651453940_at2810404M03Rik: RIKEN cDNA 2810404M03 geneAK01298569966Mm.58693.125.1825.8924.9325.361.0917.8314.4617.6416.431.75−1.54−4.339.0180341457877_atMm.102971.1AW557111Mm.102971.143.0535.1743.9440.463.3831.2123.0123.1726.283.05−1.54−3.117.0361311440064_atEtl4: enhancer trap locus 4BB502547208618Mm.169632.128.4134.5631.9331.792.3718.6923.6719.6220.772.41−1.53−3.26.0310891445080_atMm.218087.1BG072532Mm.218087.139.9240.7341.6940.692.1719.5928.9931.3526.623.93−1.53−3.132.0493561419932_s\_atMm.201472.1AW546472Mm.201472.164.7757.0650.7657.184.4239.073340.4937.592.68−1.52−3.791.027341430467_at4921511H03Rik: RIKEN cDNA 4921511H03 geneAK01487070920Mm.158494.177.678.2377.7277.892.6852.5252.5550.7751.782.71−1.5−6.861.0023641439275_s\_at9530010C24Rik: RIKEN cDNA 9530010C24 geneBG069453109279Mm.11474.124.482623.5624.72.2116.4716.6417.116.651.48−1.48−3.032.046181420687_at4932438H23Rik: RIKEN cDNA 4932438H23 geneNM_02890574387Mm.35184.168.0965.4961.7365.012.9140.6646.7448.7445.54.04−1.43−3.918.020771422273_atMmp1b: matrix metallopeptidase 1b (interstitial collagenase)NM_03200783996Mm.156951.133.3428.0928.0329.512.2519.5719.0723.3620.631.96−1.43−2.975.0419251426054_atNpy1r: neuropeptide Y receptor Y1D6381918166Mm.5112.239.9537.3938.3838.611.9325.428.8927.2927.153.22−1.42−3.051.0494571452590_a\_atGm9780 /// Plac9: predicted gene 9780 /// placenta specific 9BB609699100039175 /// 211623Mm.29491.1174.21154.86173.92167.367.32138.39109.58102.21117.5411.88−1.42−3.571.0317121446429_atP2rx4: purinergic receptor P2X, ligand-gated ion channel 4BB11094518438Mm.207333.148.2247.4241.8945.962.1636.4630.230.8232.422.2−1.42−4.398.0117181418943_atB230120H23Rik: RIKEN cDNA B230120H23 geneNM_02305765964Mm.33127.178.2687.2573.1479.744.855.8955.1757.9256.442.72−1.41−4.225.021791432791_at9030218A15Rik: RIKEN cDNA 9030218A15 geneAK02025177662Mm.159968.184.8786.9372.6781.364.8860.1161.3250.957.744.22−1.41−3.662.0223341445611_atTrappc9: trafficking protein particle complex 9BB34953576510Mm.179878.142.6453.0450.9848.623.7531.6837.7633.2534.392.69−1.41−3.081.0420561443393_atMm.131148.1BB201890Mm.131148.1101.7984.4983.9589.716.6260.1761.8370.02643.92−1.4−3.341.0393691446254_atMm.149067.1BB116559Mm.149067.118.3320.6919.2619.530.9712.8114.5214.2613.990.91−1.4−4.168.0141441429358_atFam135a: family with sequence similarity 135, member AAK01954968187Mm.87130.126.7424.6728.3526.831.5118.1420.7318.8519.341.81−1.39−3.181.035061457308_atMm.4245.1BG070176Mm.4245.153.2545.8343.5247.653.0432.4835.734.9134.411.41−1.38−3.944.0324051455000_atGpr68: G protein-coupled receptor 68BB538372238377Mm.32160.1394.3348.73339.88361.8817.77264.67271.46249.4262.828.79−1.38−4.998.0163851417017_atCyp17a1: cytochrome P450, family 17, subfamily a, polypeptide 1NM_00780913074Mm.1262.140.438.4144.2740.95230.630.9428.9629.991.64−1.37−4.234.0144271426305_atUpk1a: uroplakin 1AAF262335109637Mm.25471.147.3547.6543.0646.342.7634.5834.6732.8933.852.84−1.37−3.15.0345571429957_atKrtap26-1: keratin associated protein 26-1AK00908669533Mm.30967.155.6963.1858.2958.893.5945.5545.738.1842.943.91−1.37−3.003.0402131439674_atSlc4a8: solute carrier family 4 (anion exchanger), member 8BB43648259033Mm.209856.1169.3174.08152.95166.067.22116.68139.51107.92121.6310.17−1.37−3.562.0279511440191_s\_atLeng9: leukocyte receptor cluster (LRC) member 9AI847494243813Mm.45066.1300.04285.18259.66281.5412.12195.64215.32206.5205.286.72−1.37−5.501.0106371420720_atLOC100044234 /// Nptx2: hypothetical protein LOC100044234 /// neuronal pentraxin 2NM_016789100044234 /// 53324Mm.10099.1704.37660.98662.72676.2214.5471.43504.6510.57495.7113.63−1.36−9.072.0008331421414_a\_atSema6a: sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6ANM_01874420358Mm.9212.163.664.0254.0860.283.739.3250.0844.0644.314.06−1.36−2.91.0441431459279_atMm.126689.1BB363958Mm.126689.155.9460.4651.0255.533.5137.339.7545.9840.983.28−1.36−3.031.0389821419005_atCrybb3: crystallin, beta B3NM_02135212962Mm.40616.166.1662.9762.5163.633.0149.5643.7348.3747.512.99−1.34−3.798.0191441452243_atKcnj14: potassium inwardly rectifying channel, subfamily J, member 14BB282273211480Mm.68170.1108.27104.8194.68103.545.4785.8771.3475.4377.485.03−1.34−3.506.0250511440757_atMm.102276.1BB750206Mm.102276.142.9143.2146.844.112.330.832.1436.2932.812.9−1.34−3.057.0403191452796_atDef6: differentially expressed in FDCP 6AK01035623853Mm.60230.1144.66149.03134.86143.135.78113.52102.04105.28106.874.89−1.34−4.788.0093221459968_atMm.170575.1AW742677Mm.170575.188.8188.8680.5586.073.7660.6966.964.2364.243.83−1.34−4.067.0152671457860_atMm.25024.1BG066479Mm.25024.139.6534.6337.1137.031.727.4728.5227.5427.891.58−1.33−3.944.0170961416342_atTnc: tenascin CNM_01160721923Mm.980.194.5381.9587.4788.464.4967.5759.5575.2767.175.19−1.32−3.105.0370791424934_atUgt2b1: UDP glucuronosyltransferase 2 family, polypeptide B1BC02720071773Mm.26741.150.0156.2149.1652.093.2340.9241.6635.8739.52.58−1.32−3.042.0407321438755_atC80068: expressed sequence C80068BB32721397810Mm.188194.153.2953.2761.4156.133.5244.2139.744.9742.512.41−1.32−3.19.0395151448383_atMmp14: matrix metallopeptidase 14 (membrane-inserted)NM_00860817387Mm.19945.1423.82418.05360.61401.3321.31321.82309.99278.06303.1913.85−1.32−3.862.0240441430755_at4930452G13Rik: RIKEN cDNA 4930452G13 geneBF01861773989Mm.107775.147.4747.247.8547.572.2737.6533.235.96362.5−1.32−3.422.0271211442643_atKdm6b: KDM1 lysine (K)-specific demethylase 6BAW912463216850Mm.218492.1103.09110.15109.96107.914.6582.887.2875.5981.985.78−1.32−3.497.026851445746_atEif4h: Eukaryotic translation initiation factor 4HBB11889422384Mm.208089.153.9257.2250.9954.093.2340.7637.3245.1540.932.84−1.32−3.06.0384631441205_at1700055N04Rik: RIKEN cDNA 1700055N04 geneAW06034073458Mm.54865.188.1886.276.3683.794.763.0962.6566.9364.122.36−1.31−3.737.0343661460291_atCdk6: cyclin-dependent kinase 6NM_00987312571Mm.88747.173.3880.9568.5374.064.5560.6356.0154.4557.122.66−1.3−3.212.0441541446273_atCsmd1: CUB and Sushi multiple domains 1BB38599294109Mm.208954.1429.51457.66393.59426.7820.72332.71304.42349.6329.1614.79−1.3−3.835.0223081457346_atMm.65379.1BE649821Mm.65379.17.478.217.540.366.65.794.985.790.47−1.3−2.951.0453721421393_atGrin2d: glutamate receptor, ionotropic, NMDA2D (epsilon 4)NM_00817214814Mm.56936.177.4268.0676.574.533.5561.1253.6457.3357.624.43−1.29−2.978.0432371448786_atLOC100045163 /// Plbd1: similar to RIKEN cDNA 1100001H23 gene /// phospholipase B domain containing 1NM_025806100045163 /// 66857Mm.3311.1130.41135.4120.8128.56.63106.3996.7696.7399.944.86−1.29−3.472.0293471429862_atPla2g4e: phospholipase A2, group IVEAV235932329502Mm.158770.1127.91133.94141.19134.486.32103.46102.9107.82104.374.34−1.29−3.927.0216191445205_atMm.218112.1BM122392Mm.218112.1118.27121.04107.44115.495.6983.3286.5995.7589.274.78−1.29−3.53.0254281421865_atDbil5: diazepam binding inhibitor-like 5AK00652813168Mm.46156.196.6385.0187.6589.973.8269.0569.2274.3470.382.52−1.28−4.287.0173471427138_atCcdc88c: coiled-coil domain containing 88CAW55686168339Mm.83109.1228.03247.07234.49236.598.43176.79185.89191.17184.767.3−1.28−4.646.0101671438628_x\_atCntn3: contactin 3BB55951018488Mm.92049.1362.31362.74351.27358.719.39262.84311.68266.28279.5219.44−1.28−3.668.0373891441477_atCalu: calumeninBB12019012321Mm.215372.169.2578.176.8874.783.8855.5956.3163.0858.294.04−1.28−2.945.0422461441790_atMm.101345.1AW489900Mm.101345.1153.06149.99138.28146.645.41108.19116.23121.72114.814.97−1.28−4.335.012491447669_s\_atGng4: guanine nucleotide binding protein (G protein), gamma 4AV34790314706Mm.215394.11237.641257.841328.351271.6633.43916.31000.931066.68995.1350.1−1.28−4.592.0138851458793_atMm.182870.1BG076186Mm.182870.162.3666.1267.8565.332.6652.1351.947.5650.882.88−1.28−3.687.021311421109_atCml2: camello-like 2NM_05309693673Mm.24251.1239.07244.64211.19232.1110.96181.9185.84183.29183.274.3−1.27−4.149.0333661431147_atRint1: RAD50 interactor 1BG80774072772Mm.133300.1150.88131.25129.19136.927.24110.96111.2100.08107.674.52−1.27−3.425.0350881445835_atMm.76734.1AW123001Mm.76734.1101.3990.7898.1496.863.5278.8472.7478.5876.313.26−1.27−4.283.0129821426492_atTdp1: tyrosyl-DNA phosphodiesterase 1AK014855104884Mm.196233.1178.5163.74167.38170.456.9134.68132.37140.02135.045.34−1.26−4.059.017361449537_atMsh5: mutS homolog 5 (E. coli)NM_01360017687Mm.24192.199.27104.84114.17106.255.2374.3291.7586.4884.255.76−1.26−2.828.0479591452035_atCol4a1: collagen, type IV, alpha 1BF15863812826Mm.738.1402.93451.75470.78441.622.29326.93339.27389.33350.2621.58−1.26−2.944.0422621438203_atScarf2: Scavenger receptor class F, member 2BF467245224024Mm.33775.239.4242.743.1541.961.9835.130.7734.8533.311.89−1.26−3.152.0345541444108_atDnajc25: DnaJ (Hsp40) homolog, subfamily C, member 25AI41400472429Mm.211696.1179.21171.26167.4172.064.82135.68129.96144.72136.885.35−1.26−4.882.0083771444810_atMm.182531.1BG065305Mm.182531.150.5649.9248.849.672.237.338.7440.7139.272.29−1.26−3.278.030641446975_atCasz1: Castor homolog 1, zinc finger (Drosophila)BE94994569743Mm.150579.1144.35160.17148.64150.895.83118.12130.17112.08120.056.03−1.26−3.679.0212681447433_atWdfy3: WD repeat and FYVE domain containing 3BB74331672145Mm.44007.1321.95375.48343.8347.0216.18248.72279.7295.72274.7714.46−1.26−3.329.0296791456921_atMm.151095.1BE956991Mm.151095.187.3287.778.9284.613.6473.6868.1759.6567.414.72−1.26−2.889.0480631421821_atLdlr: low density lipoprotein receptorAF42560716835Mm.3213.1426.43462.69401.82429.9319.48357.56352.59327.4234511.13−1.25−3.785.0291891426591_atGfm2: G elongation factor, mitochondrial 2BB497484320806Mm.219675.1130.64135.94132.44132.954.15113.34103.74104.18106.774.96−1.25−4.05.0164531450971_atGadd45b: growth arrest and DNA-damage-inducible 45 betaAK01042017873Mm.1360.1509.27481.26432.79473.924.02366.48369.13409.23380.6316.47−1.25−3.203.0390181434973_atCar7: carbonic anhydrase 7BE65038012354Mm.63694.1327.74346.25328.23333.499.26260.01283.81254.63266.1610.67−1.25−4.767.0092991435116_at4933403G14Rik: RIKEN cDNA 4933403G14 geneBB21900374393Mm.41709.1176.69154.36181170.688.71130.52141.79136.03136.035.72−1.25−3.327.036381440834_atSlc5a10: solute carrier family 5 (sodium/glucose cotransporter), member 10BB502441109342Mm.41011.1125.08134.03115.77124.556.7798.9199.31101.5799.663.46−1.25−3.275.0470421460478_at2200002J24Rik: RIKEN cDNA 2200002J24 geneAK00862069147Mm.45301.1152.68143.05136.21143.495.49108.37129.08108.87115.247.8−1.25−2.961.047541417170_atLztfl1: leucine zipper transcription factor-like 1NM_03332293730Mm.133164.1432.72440.32460.48444.2212.58580.2528555.97554.3916.921.255.225.0079561417791_a\_atZfml: zinc finger, matrin-likeBM23843118139Mm.4503.1603.83584.34597.44594.6613.66749.91678.98797.88742.2636.461.253.791.0425021423444_atRock1: Rho-associated coiled-coil containing protein kinase 1BI66286319877Mm.6710.1468.92526.5521.12504.920.54657.71599.07631.15629.0918.381.254.506.0110781425095_atBC002059: cDNA sequence BC002059BC002059213811Mm.130624.1138.71131.84140.27136.084.63174.89169.53167.14170.44.41.255.375.0058321425338_atPlcb4: phospholipase C, beta 4BB22403418798Mm.132097.191.6389.897.5293.364.77123.22113.3115.1116.934.461.253.61.0227141427089_atCcnt2: cyclin T2BI87215172949Mm.45584.1268.1284.73311.81289.115.34390.92349.47351.96361.915.931.253.292.0302111437461_s\_atRnpc3: RNA-binding region (RNP1, RRM) containing 3BB55744167225Mm.58104.2131.32150.69145.85142.797.28173.91164.41196.42178.359.791.252.914.0479481452659_atDek: DEK oncogene (DNA binding)AK007546110052Mm.28343.11080.091042.171035.411051.2819.331396.441259.971280.061310.8544.071.255.393.0156821443857_atHook3: hook homolog 3 (Drosophila)BB825115320191Mm.63527.1195.2202.63236.78211.2813.35254.63257.81281.53264.669.711.253.233.0363321416421_a\_atSsb: Sjogren syndrome antigen BBG79684520823Mm.10508.1378.2349.83335.58354.2213.47472.79403.84464.8446.7222.641.263.511.0343631424410_atTtc8: tetratricopeptide repeat domain 8BC01752376260Mm.32328.1397.32437.03429.19422.114.98565.57515.61514.96532.8518.41.264.667.0105041424591_at5830433M19Rik: RIKEN cDNA 5830433M19 geneBC02006767770Mm.35170.1200.01179.9218.2198.4611.96239.31247.62263.25250.48.581.263.528.0284931429490_atRif1: Rap1 interacting factor 1 homolog (yeast)AK01831651869Mm.27568.189.6786.698.1592.224.7107.72117.36123.37116.355.511.263.329.0302341429623_atZfp644: zinc finger protein 644AV26118752397Mm.220900.1525.47521.94518.53521.499.12721.36625.1622.19656.4732.841.263.96.0458511450994_atRock1: Rho-associated coiled-coil containing protein kinase 1BI66286319877Mm.6710.1370.11418.42420.44404.2119.67513.89485.75527.24507.5515.061.264.171.0160751453162_atUtp11l: UTP11-like, U3 small nucleolar ribonucleoprotein, (yeast)AK00880167205Mm.156860.2196.24213.14218.74210.7510.18263.21266.83263.02264.696.241.264.517.0163141460381_atZfp772: zinc finger protein 772BC023179232855Mm.217124.195.66105.05112.16104.737.4135.92127.51130.19131.613.591.263.265.0494691435348_atD930009K15Rik: RIKEN cDNA D930009K15 geneBQ177188399585Mm.21093.1222.36216.01229.65222.376.92291.64279.52265.29279.289.071.264.985.0090081435918_atFam107a: family with sequence similarity 107, member ABB277054268709Mm.40462.1471.48468.07506.76482.215.99633.2638.46555.75608.228.571.263.848.0285281436116_x\_atAppl1: adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1AI58578272993Mm.36762.1209.7207.81233216.299.49259.93259.84299.28273.0313.621.263.418.0320371455095_atHist2h2be: histone cluster 2, H2beBB667233319190Mm.5220.1209.9227.54206.27214.258.88249.8285.1275.44269.8712.241.263.678.0249421415855_atKitl: kit ligandBB81553017311Mm.4235.1386.79459.82395.51414.1625.01523.41530.84516.9524.28.051.274.189.0376431424043_atPpil4: peptidylprolyl isomerase (cyclophilin)-like 4BC00465267418Mm.38927.1499.36456.12462.31473.9915.39640.42580.85585.05600.3320.621.274.91.0097271456319_atMm.196322.1BG065719Mm.196322.172.6871.170.9271.563.4391.2398.4183.2790.985.391.273.041.0476361436446_at2310007O11Rik: RIKEN cDNA 2310007O11 geneBQ17646974177Mm.37929.1376.59401.5471.85416.4729.74526.38519.75546.66530.2910.311.273.615.0495951440902_atErmn: ermin, ERM-like proteinAI85446077767Mm.40963.1995.28938.89788.71906.1963.371063.381252.691138.131150.557.681.272.851.0468271442982_atCcdc66: coiled-coil domain containing 66BG075305320234Mm.216841.2251.06244.55253.12249.238.21327.06291.38332.61316.4414.241.274.089.0233681455738_atCcdc55: coiled-coil domain containing 55BB066444237859Mm.116117.1143.35137.24143.89141.695.19173.48193.62170.54179.249.331.273.519.0364181423445_atRock1: Rho-associated coiled-coil containing protein kinase 1BI66286319877Mm.6710.1309.17340.28336.26328.9111.68441.93397.23419.64420.3614.011.285.013.008061425575_atEpha3: Eph receptor A3M6851313837Mm.1977.1154.74123.67130.43135.5710.09166.22184.06172.18174.086.611.283.192.0408151452110_atMtrr: 5-methyltetrahydrofolate-homocysteine methyltransferase reductaseBB757908210009Mm.205514.1230193.89239.93221.3914.29303.1286.52257.77282.5914.111.283.048.0381061456510_x\_atHigd1c /// Mettl7a2: HIG1 domain family, member 1C /// methyltransferase like 7A2BB703414380975 /// 393082Mm.220975.3254.81284.04272.16269.2612.51360.13345.26329.26344.5311.31.284.466.0113761436139_atMm.115096.1AV328974Mm.115096.1143.44152.61156.78151.256.56187.47186.62206.57193.797.31.284.336.0125971443986_atCdc73: cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)BB211070214498Mm.123792.1187.04152.7186.86175.6511.83226.38211.75235.19224.697.831.283.458.0324411428052_a\_atZmym1: zinc finger, MYM domain containing 1BC02775068310Mm.80623.2243.94257.89248.99250.747.83333.63284.92348.43323.0419.291.293.473.0489661439103_atCdc73: cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)BB183750214498Mm.221175.1158.8159.47161.08159.694.05204.74194.33216.84205.527.051.295.634.009341449972_s\_atBC018101 /// Zfp97: cDNA sequence BC018101 /// zinc finger protein 97NM_01176522759 /// 449000Mm.4596.1223.44213.43207.91214.676.04273.53278.11277.08276.35.891.297.301.0018771450954_atYme1l1: YME1-like 1 (S. cerevisiae)BB82616827377Mm.23335.1435.19451.57452.69446.9111.12585.37567.45582.19578.3310.671.298.528.0010451431381_at3110005L24Rik: RIKEN cDNA 3110005L24 geneAA61158973091Mm.158940.170.7760.4465.4765.744.3786.1681.6587.4484.783.611.293.36.0298591436157_atCcar1: cell division cycle and apoptosis regulator 1AW53804967500Mm.196371.2926.59930.69999.8952.0625.611267.851302.871118.491228.958.621.294.328.0273731447913_x\_atAkap9: A kinase (PRKA) anchor protein (yotiao) 9BB109183100986Mm.131768.1146.82157.46168.26157.887.16189.82197.27223.68203.5310.641.293.559.0293881452750_at5530601H04Rik: RIKEN cDNA 5530601H04 geneBB82084671445Mm.44816.1205.41198.8205.2203.725.39284.91264.22236.06261.8715.281.293.59.0498521456027_atRbm41: RNA binding motif protein 41AV315180237073Mm.86328.1127.25115.89115.45119.55.25163.33154.15144.21153.936.311.294.194.0147351427518_atD10627: cDNA sequence D10627AI892455234358Mm.10509.1103.259292.8595.424.51125.7116.81129.15123.724.841.34.281.0129741439272_atLcorl: ligand dependent nuclear receptor corepressor-likeBB183240209707Mm.32012.3188.36191.61221.02200.5111.72243.12247.32291.93260.5416.551.32.96.0473711457897_atIqce: IQ motif containing EAV24551874239Mm.23778.149.851.4846.7348.952.6467.0959.4862.9563.42.671.33.847.018351416958_atNr1d2: nuclear receptor subfamily 1, group D, member 2NM_011584353187Mm.26587.11633.21745.681893.361757.779.822412.632241.992271.592306.3256.261.315.618.0067531434150_a\_atHigd1c /// Mettl7a1 /// Mettl7a2: HIG1 domain family, member 1C /// methyltransferase like 7A1 /// methyltransferase like 7A2AV171622380975 /// 393082 /// 70152Mm.220975.2408.26453.92404.75422.3218.25573.73550.07527.89552.1114.531.315.564.0058991451805_atPhip: pleckstrin homology domain interacting proteinBI73735283946Mm.54737.1106.83111.25103.61106.995.12145.62136.2138.98139.785.311.314.445.011321429690_at1300003B13Rik: RIKEN cDNA 1300003B13 geneAK00487074149Mm.30767.1228.26240.06231.88233.597.01314.78284.94324.72307.1213.191.314.923.0154981436045_atTsga10: testis specific 10AV377349211484Mm.40999.1286259.77259.32267.5610.91367.22347.37338.68351.3512.131.315.137.0070161447854_s\_atHist2h2be: histone cluster 2, H2beAV127319319190Mm.200193.1232.85234.47231.87232.955280.32310.98325.95305.4814.431.314.749.0270131457584_atAI848100: expressed sequence AI848100AV377565226551Mm.127029.134.731.1329.5131.592.4342.2738.3443.4941.422.191.313.006.0402341420340_atCspp1: centrosome and spindle pole associated protein 1NM_026493211660Mm.45963.1119.71106.7494.09106.777.66147.98143.18129.63140.555.941.323.484.0278251424672_atDmxl1: Dmx-like 1BC020141240283Mm.142349.1380.03401.43455.21411.7623.28531.19508.47587.41542.1424.051.323.895.017651429907_at1700094D03Rik: RIKEN cDNA 1700094D03 geneAK00706073545Mm.3765.1181.4137.48151.82157.7113.95214.27186.93222.86208.5911.291.322.834.049541438736_atThoc2: THO complex 2BB703762331401Mm.22663.3462.35480.2434.96458.9914.62651.32562.68600.5604.4126.321.324.829.0153791436540_atMirlet7d: microRNA let7dBQ031149387247Mm.26586.1277.53305.59289.56290.610.88429.91373.75349.02383.8324.531.323.475.0458131437556_atZfhx4: zinc finger homeodomain 4BF14759380892Mm.133521.1130.93125.2162.62139.3312.3185.34169.98198.7184.089.221.322.911.0478731438937_x\_atAng: angiogenin, ribonuclease, RNase A family, 5AI38558611727Mm.202665.1118.78104.18104.62109.576.7147.4157.16128.95144.749.331.323.062.0427711445723_atPlcl1: phospholipase C-like 1BB451636227120Mm.212111.1161.24179.97157.21165.829.04219.65216.86219.65219.063.151.325.562.0186831436213_a\_at1110028C15Rik: RIKEN cDNA 1110028C15 geneAV02301868691Mm.43671.2129.89121.93141.37131.166.56170.75160.26192.72174.389.891.333.642.0278961434097_atD10627: cDNA sequence D10627BM218328234358Mm.108679.1157.36140.94141.3146.466.51186.83190.43209.03195.088.051.334.697.0103371424854_atHist1h4a /// Hist1h4b /// Hist1h4f /// Hist1h4i /// Hist1h4m: histone cluster 1, H4a /// histone cluster 1, H4b /// histone cluster 1, H4f /// histone cluster 1, H4i /// histone cluster 1, H4mBC019757319157 /// 319158 /// 319161 /// 326619 /// 326620Mm.14775.190.291.1174.5885.876.66126.65112.52107.29115.46.441.343.186.0334081451640_a\_atRsrc2: arginine/serine-rich coiled-coil 2BC008229208606Mm.27799.1461.19403.54438.8743517.55657.47539.86546.65581.7338.041.343.502.0435551433743_atDach1: dachshund 1 (Drosophila)BG07582013134Mm.10877.166.8458.0768.8264.934.0392.8778.2390.2987.114.721.343.576.0242181435230_atAnkrd12: ankyrin repeat domain 12BB277613106585Mm.34706.1478.84465.52467.21470.689.21674.29603.84613.33628.8525.61.345.814.0163111437433_atB3galt2: UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2BB25492226878Mm.110912.1179.28147.72150.89159.4210.59229.18201.4218.88215.948.771.354.109.0158011418526_atSfrs13a: splicing factor, arginine/serine-rich 13ANM_01017814105Mm.10229.1259.28248.6283.51264.5410.63388.1363.75328.4359.9917.791.364.606.0159411418527_a\_atSfrs13a: splicing factor, arginine/serine-rich 13ANM_01017814105Mm.10229.1364.64372.34392.31377.1811.55568.88479.73488.76512.7628.771.364.373.0289011449571_atTrhr: thyrotropin releasing hormone receptorM5981122045Mm.3946.1238.58208.05216.25221.249.75322.89261.02319.94300.8920.541.363.503.0425071436156_atCcar1: cell division cycle and apoptosis regulator 1AW53804967500Mm.196371.2523.53537.22548.21537.312.02768.5751.71672.18730.1630.991.365.801.0151391439340_atD630036G22Rik: RIKEN cDNA D630036G22 geneBB501833442807Mm.170453.138.1948.1542.3342.793.5759.6362.3753.0458.223.831.362.945.0424111423084_atB3galt2: UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2BB22390926878Mm.123510.1334.31321.88340.28333.247.32463.78425.19478.35455.3716.851.376.649.0092631448738_atCalb1: calbindin 1BB24603212307Mm.354.1170.68148.33184.23167.1511.55215.59234.09234.64228.28.231.374.305.0156531446261_atD1Ertd507e: DNA segment, Chr 1, ERATO Doi 507, expressedBG06811152356Mm.155161.138.4636.429.5334.843.4349.1848.3546.5847.91.591.373.454.044991455686_atLcorl: ligand dependent nuclear receptor corepressor-likeBB077342209707Mm.131615.1266.79206.29270.23247.6120.94332.55337.08343.37338.767.441.374.101.0369741458112_atAdarb2: adenosine deaminase, RNA-specific, B2BB52755094191Mm.190112.1305.74288.51279.66290.610.51419.59381.19394.81398.5313.781.376.229.0042231458571_atD430047D06Rik: RIKEN cDNA D430047D06 geneBB488016320716Mm.135160.128.9725.0230.1627.762.6237.7637.6438.4437.932.011.373.076.0404161423982_atSfrs13a: splicing factor, arginine/serine-rich 13AAF06049014105Mm.10229.2581.56587.09661.64610.6226.81869.42853.14830.5852.3913.881.48.009.0040631433322_at4930529F21Rik: RIKEN cDNA 4930529F21 geneAK01593275226Mm.159470.136.5132.3729.7332.882.6250.844.2441.6346.033.391.43.069.0405681447815_x\_at6430527G18Rik: RIKEN cDNA 6430527G18 geneBB057169238330Mm.161505.150.6441.913944.64.8160.4463.7164.8463.0541.412.95.0436751419014_atRhag: Rhesus blood group-associated A glycoproteinNM_01126919743Mm.12961.121.8219.7318.1619.941.7131.7724.5128.6828.252.311.422.886.0493391456934_atCalb1: calbindin 1BB17777012307Mm.121403.1238.21187.65224.7216.715.62337.85296.9290.88308.6715.521.424.176.013961430781_atAk7: adenylate kinase 7AV25629878801Mm.59172.1150.21147.82138.59144.926.53228.65207.74185.15207.0713.381.434.173.0267151437980_at9130230N09Rik: RIKEN cDNA 9130230N09 geneBB8149471E+08Mm.190421.125.621.1426.7124.542.435.3733.6435.1935.031.961.433.386.0293381439820_atMm.167368.1BB364548Mm.167368.187.3176.9569.2777.646.01123.88111.0997.3111.058.061.433.323.0329631457373_atMm.135415.1BB495006Mm.135415.1152.34155.53181.84163.7710.45251.24251.9200.53234.9617.831.433.444.0366951443050_atFn3krp: fructosamine 3 kinase related proteinBB072270238024Mm.117394.1501.97591.9679.4590.9952.8847.83830.92870.55849.7515.11.444.712.0312891458040_atD7Wsu130e: DNA segment, Chr 7, Wayne State University 130, expressedBM21383228017Mm.33177.147.5946.8651.4149.053.0772.6474.8865.471.033.681.454.587.0108981455087_atD7Ertd715e: DNA segment, Chr 7, ERATO Doi 715, expressedAV32849852480Mm.21243.1180.24158.92168.84169.316.5257.55245.19236.27246.396.631.468.302.0011521441938_x\_atCables1: CDK5 and Abl enzyme substrate 1BB07177763955Mm.63141.1103.77103.88145.15118.0114.28166.82182.08170.07173.236.021.473.563.044951450208_a\_atElmo1: engulfment and cell motility 1, ced-12 homolog (C. elegans)NM_080288140580Mm.214934.1157.5179.25187.87174.6310.48264.19303.84222.94263.6924.151.513.383.0495391419347_x\_atSvs5: seminal vesicle secretory protein 5NM_00930120944Mm.140154.115.9816.3112.514.931.725.2420.4522.6922.861.691.533.304.0298121448421_s\_atAspn: asporinNM_02571166695Mm.25755.115.7817.9614.4815.962.1422.9826.3724.4424.731.881.553.076.037891417602_atPer2: period homolog 2 (Drosophila)AF03583018627Mm.8471.1165.31180.23249.94198.5826.58347.55318.29266.59310.7524.11.563.126.0357791422163_atSh3pxd2a: SH3 and PX domains 2ANM_00801814218Mm.20446.19.849.7312.2511.011.4515.7718.5916.6217.161.591.562.859.0464211457534_atMm.210151.1BB481074Mm.210151.130.9338.427.1232.44.7947.7155.551.0150.793.891.572.981.0428741459281_atMm.208534.1BB182935Mm.208534.14.976.955.755.730.898.919.479.219.130.811.592.817.0484431436330_x\_atGm7072: predicted gene 7072BG244780631624Mm.25705.167.6368.1971.6969.423.45102.57105.84126.76111.618.061.614.813.021511439717_atGabrg3: gamma-aminobutyric acid (GABA) A receptor, subunit gamma 3BB31610014407Mm.44821.118.6220.1429.1822.493.9436.5437.0338.2437.312.891.663.033.0432281437303_atIl6st: interleukin 6 signal transducerBI10291316195Mm.96748.1203.93239.51305.91249.7430.94374.55491.68387.59418.5738.631.683.412.0290311430444_at0610006L08Rik: RIKEN cDNA 0610006L08 geneAK00225576253Mm.81063.111110.161.841.531.841.710.141.713.259.0318311430376_atLrrc9: leucine rich repeat containing 9AK01954578257Mm.160065.119.0720.7919.3819.771.8533.093829.8334.223.681.733.511.0401271425618_atDhx9: DEAH (Asp-Glu-Ala-His) box polypeptide 9U9192213211Mm.20000.15.675.618.636.651.1511.4611.6112.7111.790.861.773.591.0262011442809_atScn9a: sodium channel, voltage-gated, type IX, alphaBB45227420274Mm.153332.116.8619.4815.0717.42.1234.0234.2225.0131.013.31.783.473.0329831419962_atMm.195371.1C80871Mm.195371.18.348.475.997.41.4511.8114.2114.2713.391.191.813.19.0350351446552_atSlc12a3: solute carrier family 12, member 3BB50357420497Mm.209611.110.868.4312.5810.541.3514.8220.2322.6219.222.351.823.202.0451171420547_atGalc: galactosylceramidaseBF16811914420Mm.5120.168.8769.1979.1572.087153.99147.99103.53135.1716.531.883.514.0462041437824_atGrid2: glutamate receptor, ionotropic, delta 2BB33454214804Mm.131503.16.784.297.466.161.3912.7210.5311.6611.711.191.93.028.0399881421317_x\_atMyb: myeloblastosis oncogeneNM_03359717863Mm.1202.132.9426.3121.7727.114.3657.8355.944.5652.874.671.954.033.0158381449807_x\_atGabra2: gamma-aminobutyric acid (GABA) A receptor, subunit alpha 2AV37924714395Mm.45112.2960.491094.931173.791074.3177.381969.952148.452248.452114.5690.211.978.753.0010411454561_at9430087B13Rik: RIKEN cDNA 9430087B13 geneAK02050877437Mm.159920.17.72.56.095.581.649.8212.7911.8711.511.292.062.84.0497781430218_at4933424M12Rik: RIKEN cDNA 4933424M12 geneAK01689967548Mm.148731.17.547.784.316.611.81212.7917.2214.021.892.122.838.0471031419321_atF7: coagulation factor VIINM_01017214068Mm.4827.17.759.9812.29.722.0625.6818.5618.0320.692.672.133.255.0341361453435_a\_atFmo2: flavin containing monooxygenase 2AK00975355990Mm.34838.118.1418.3317.8618.112.0939.9543.6333.3238.963.522.155.095.0119211443577_atMm.72499.1AV261494Mm.72499.14.985.785.825.490.5110.7410.7214.7112.041.382.24.468.0295121454638_a\_atPah: phenylalanine hydroxylaseAW10692018478Mm.2422.213.362.372.270.754.525.685.265.110.582.252.985.0439831420300_atMm.45112.2AV379247Mm.45112.235.834.1330.0633.092.9669.573.2481.0574.483.972.258.355.0015661420774_a\_at4930583H14Rik: RIKEN cDNA 4930583H14 geneNM_02635867749Mm.62589.18.564.515.516.462.0715.7812.717.3415.412.22.392.963.041651440510_atC430002N11Rik: RIKEN cDNA C430002N11 geneBB407702319707Mm.140067.111110.242.962.232.232.440.262.444.09.015191442860_atDgkb: diacylglycerol kinase, betaBB429621217480Mm.208793.12.665.719.125.742.0215.9112.7314.1314.181.372.473.467.0315371440754_atMm.193602.1BG797192Mm.193602.17.313.583.324.91.7312.8911.312.3312.31.072.513.633.0301591429481_atNck2: non-catalytic region of tyrosine kinase adaptor protein 2AK01477217974Mm.144978.13.36.212.64.11.5110.6611.019.6310.451.232.553.258.0329881423340_atTcfap2b: transcription factor AP-2 betaAV33459921419Mm.4795.111.873.532.10.95.096.494.955.520.592.633.189.0410731425434_a\_atMsr1: macrophage scavenger receptor 1L0427420288Mm.1227.23.9515.873.451.568.987.7510.519.071.172.632.889.0487761418783_atTrpm5: transient receptor potential cation channel, subfamily M, member 5AF22868156843Mm.143747.19.4710.653.887.722.6521.4420.0919.8920.421.382.654.254.0237461453812_atJakmip2: janus kinase and microtubule interacting protein 2AK01829576217Mm.165340.13.536.646.075.212.4217.2411.9913.6114.221.972.732.895.0465621455444_atGabra2: gamma-aminobutyric acid (GABA) A receptor, subunit alpha 2BB33933614395Mm.121933.1691.96660.47646.13666.5419.811812.11792.151931.731843.5448.152.7722.607.0004091451510_s\_atOlah: oleoyl-ACP hydrolaseBC02500199035Mm.13808.11.43.41.492.140.766.426.84.876.040.912.823.291.0317511421044_atMrc2: mannose receptor, C type 2BB52840817534Mm.9020.115.574.993.851.5212.948.4311.3710.961.442.853.393.0275661432837_at2700080J24Rik: RIKEN cDNA 2700080J24 geneAK01254267969Mm.158180.12.822.15.553.431.439.268.5711.039.771.062.853.571.0267431421738_atGabra2: gamma-aminobutyric acid (GABA) A receptor, subunit alpha 2NM_00806614395Mm.5304.1586.9565.56595.82582.4512.021703.771644.431765.131705.6339.552.9327.174.0005221459553_atMm.172145.1BG068521Mm.172145.11.753.541.352.010.935.985.427.256.310.833.143.445.0267061451349_atEfcab7: EF-hand calcium binding domain 7BC020077230500Mm.207859.143.0556.4659.2953.0612.18177.8140.15182.95166.9913.963.156.152.003761430751_atSerpina3i: serine (or cysteine) peptidase inhibitor, clade A, member 3IAK019935628900Mm.194525.12.242.063.422.440.877.197.638.767.80.733.24.739.0097071424233_atMeox2: mesenchyme homeobox 2BC00207617286Mm.153716.11.623.864.833.331.8213.338.699.6810.71.623.213.031.0394251443865_atGabra2: gamma-aminobutyric acid (GABA) A receptor, subunit alpha 2BQ17458914395Mm.45112.1304.6268.13278.64283.8111.89975.16892.33949.03939.0424.633.3123.956.0002071457044_atMacc1: metastasis associated in colon cancer 1BB007136238455Mm.31376.13.073.523.293.311.4511.729.5914.0511.651.883.523.507.0273541450573_atAmh: anti-Mullerian hormoneNM_00744511705Mm.57098.13.062.534.463.671.612.210.1716.7413.021.963.543.693.0224961449393_atLOC100046930 /// Sh2d1a: similar to T cell signal transduction molecule1 SAP /// SH2 domain protein 1ANM_011364100046930 /// 20400Mm.20880.14.555.671.623.591.718.4712.9610.7614.072.313.923.663.0249421419100_atSerpina3n: serine (or cysteine) peptidase inhibitor, clade A, member 3NNM_00925220716Mm.22650.1511.9422.34563.08502.6149.22450.792136.391426.572004.13303.073.994.89.035491419477_atClec2d: C-type lectin domain family 2, member dNM_05310993694Mm.197536.11.221.2211.150.274.364.15.664.650.64.065.296.0159731421564_atSerpina3c: serine (or cysteine) peptidase inhibitor, clade A, member 3CNM_00845816625Mm.14191.110.954.359.18.243.6841.6832.831.4135.243.54.285.313.0060741436170_a\_atCsn1s2a: casein alpha s2-like ABF11930512993Mm.4908.31.121.53.942.011.347.358.4110.818.91.514.433.411.0275671457274_atGm13103: predicted gene 13103BB555205194225Mm.17793.11.691.224.482.471.2211.989.9713.9611.891.584.814.705.010753
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==========

Here, we provide evidence supporting a role for MSK1 as a critical component of a neuroprotective response pathway that limits cell death resulting from SE. Using a 3-day post-SE time point, we observed extensive cell death in the CA1, CA3, and hilar regions of the hippocampus and relatively modest cell death in the GCL. This cell death pattern is consistent with an extensive literature on pilocarpine-evoked cell death ([@bibr57-1759091417726607]; [@bibr26-1759091417726607]; [@bibr8-1759091417726607]; [@bibr75-1759091417726607]; [@bibr69-1759091417726607]). Further, this pattern of cell death was largely intact in *MSK1* null mice; hence, MSK1 did not consistently confer vulnerability to any additional cell types; rather, the loss of MSK1 exacerbated cell death in inherently vulnerable cell populations (i.e., pyramidal neurons of CA1 and CA3 cell layers). Interestingly, cell death in the hilus was not affected in *MSK1* null mice. One possible explanation for this is that SE has been shown to trigger very high levels of hilar interneuron cell death ([@bibr9-1759091417726607]; [@bibr16-1759091417726607]; [@bibr68-1759091417726607]), and thus, this high degree of cell death could preclude any effects of *MSK1* deletion. However, it is also worth noting that our immunofluorescent labeling revealed limited MSK1 expression in hilar neurons. Could this limited expression of MSK1 in hilar neurons contribute to their inherently high level of sensitivity to SE? Clearly, further studies that focus on hilar interneurons and MSK1 signaling will be needed to address this idea. As noted above, the GCL is relatively resistant to the excitotoxic effects of pilocarpine-evoked SE ([@bibr57-1759091417726607]; [@bibr26-1759091417726607]; [@bibr13-1759091417726607]; [@bibr53-1759091417726607]). Given the high level of MSK1 expressed in the GCL, we speculated that *MSK1* null mice could exhibit GCL vulnerability to SE. However, the data presented here showed that *MSK1* deletion did not consistently enhance GCL neuronal sensitivity to SE (of note, we did observe that one out of 18 *MSK1* null animals showed marked SE-evoked GCL degeneration, see [Figure 4(a)](#fig4-1759091417726607){ref-type="fig"}). These data coupled with the data from the CA1 and CA3 cell layers indicate that factors working independently of the MSK1 signaling network regulate SE-evoked cell death in the GCL layer of the hippocampus.

Here, we detected robust inducible MSK1 phospho-activation in response to seizure activity, and that under control conditions, MSK1 activation was relatively low throughout the hippocampus. This pattern of robust SE-evoked MSK1 activity is consistent with work showing that the ERK/MAPK and P38 pathways (the two upstream effectors of MSK1) are activated following multiple seizure induction paradigms in the hippocampus ([@bibr5-1759091417726607]; [@bibr28-1759091417726607]; [@bibr41-1759091417726607]; [@bibr27-1759091417726607]; [@bibr36-1759091417726607]; [@bibr16-1759091417726607]; [@bibr47-1759091417726607]). This dynamic, inducible, activation of MSK1 raises a question: Is SE-evoked MSK1 activity required to confer neuroprotection or is the tonic, basal level of MSK1 activity sufficient to drive neuroprotection. As noted earlier, [@bibr48-1759091417726607] reported striatal deterioration in aged MSK1 null mice. This finding could be used to support the idea that the disruption of basal MSK1 activity is sufficient to drive vulnerability to stressful stimuli. However, it is also worth noting that a number of studies have shown that the disruption of basal ERK/MAPK activity does not affect cell health, but rather leads to the abrogation of an evoked neuroprotective response ([@bibr30-1759091417726607]; [@bibr42-1759091417726607]; [@bibr59-1759091417726607]; [@bibr58-1759091417726607]; [@bibr55-1759091417726607]). Hence, it is likely that both basal and stress-evoked MSK1 signaling contribute to the neuroprotective response. Here, it is also worth noting that *MSK1* deletion did not affect hippocampal neuronal cell viability under normal physiological conditions. Rather, the *MSK1* null cell death phenotype was only revealed under stress conditions. In some respects, this is consistent with studies showing that the disruption of CREB (a downstream MSK1 target) does not, by itself, trigger cell death, but does increase neuronal vulnerability to excitatory insults ([@bibr44-1759091417726607]; [@bibr45-1759091417726607]). Notably, as with CREB, MSK1 has been implicated in a range of plasticity-dependent processes, including learning and memory, and activity dependent synapse formation ([@bibr17-1759091417726607]; [@bibr18-1759091417726607]; [@bibr39-1759091417726607]). Together, these data indicate that MSK1 plays at least two distinct roles in the central nervous system: one that couples synaptic activity to changes in functional plasticity and a second role as an effector of neuroprotective signaling. Further work will be required to determine the relative contribution of CREB to the neuroprotective effects elicited by MSK1 signaling.

Given the enhanced cell death phenotype, it was surprising to find that *MSK1* null neurons exhibited weaker NMDA-evoked excitatory drive compared to WT neurons, as assessed using Ca^2+^ imaging. Interestingly, reduced excitability may be consistent with studies showing that *MSK1* null mice exhibit reduced functional plasticity, including activity-dependent spine formation, synaptic scaling, and cognition ([@bibr17-1759091417726607]; [@bibr18-1759091417726607]; [@bibr39-1759091417726607]). Further, the weak-evoked Ca^2+^ response in *MSK1* null neurons indicates that the enhanced cell death phenotype likely cannot be ascribed to aberrant excitatory drive. Rather, these data point to the compromised expression of neuroprotective genes and gene networks in *MSK1* null neurons.

Could the enhanced SE-evoked cell death in *MSK1* null mice result from dysregulated apoptotic and necrotic cell death mechanisms? With respect to apoptosis, extensive work in nonneuronal cells has shown that MSK regulates cell survival via the regulation of antiapoptotic cell death mechanisms ([@bibr54-1759091417726607]; [@bibr38-1759091417726607]; [@bibr24-1759091417726607]; [@bibr37-1759091417726607]; [@bibr56-1759091417726607]; [@bibr32-1759091417726607]; [@bibr52-1759091417726607]), including the regulation of NF-κB, BAD, and caspase activation ([@bibr65-1759091417726607]; [@bibr25-1759091417726607]). Further, the CREB/CRE transcriptional pathway, a principal target of MSK1, has also been shown to regulate apoptotic cell death (reviewed in [@bibr64-1759091417726607]).

In contrast to the extensive work on MSK and apoptotic cell death, to our knowledge, limited work has explored the potential contribution of MSK signaling to necrotic cell death. Necrotic cell death is typically associated with elevated intracellular Ca^2+^ levels, rapid ATP depletion, and mitochondrial swelling; these and other events lead to the collapse of the membrane potential and the rupturing of the plasma membrane. Although our data did not identify an effect of MSK1 deletion on Ca^2+^ homeostatic, or evoked responses, our array data indicate that MSK1 regulates the expression of several genes that could affect neuronal vulnerability. Many of these genes are associated with oxidation/reduction chemistry (*alcohol dehydrogenase*,*phenylalanine hydroxylase*, *NOS2*, *sulfide quinone reductase*) and membrane receptor signaling (*epidermal growth factor receptor*,*GABA-A receptor subunit alpha 2*) and cellular transport (e.g., *alpha-synuclein*,*EHD2*, *coronin*).

Interestingly, one of the strongest effects of MSK1 deletion was on the expression of galactosylceramidase (Galc): ∼14-fold decrease in expression. Galc is highly expressed in both neurons and oligodendrocytes and serves as a key enzyme in the metabolism of galactolipids. Loss-of-function mutations in Galc underlie the development of Krabbe disease in humans ([@bibr72-1759091417726607]). Interestingly, the *Twitcher* mouse line (a model of Krabbe disease) bred onto a C57BL/6 J and 129SvEv mixed background shows spontaneous neuronal cell death within the hippocampus ([@bibr70-1759091417726607]). These observations raise the prospect that reduced Galc expression in *MSK1* null mice may also contribute to the cell death phenotype reported here. However, it is worth noting that the developmental and motor phenotypes associated with the *Twitcher* line (i.e., stunted growth, twitching and limb weakness reported by [@bibr23-1759091417726607]) were not observed in the *MSK1* null line. Clearly, the list of genes that are regulated by MSK1 is extensive, and as such, the cell death phenotype observed here could have resulted from a complex interplay of affected genes and gene networks. It is also worth noting that the effects of *MSK1* deletion on cell type-specific neuroprotective genes may have evaded detection, given that the whole hippocampus was used for our array profiling.

In conclusion, the data reported here reveal that MSK1 regulates neuroprotective signaling in the CA1 and CA3 sublayers of the hippocampus. This effect occurs on a cellular level and is not associated with increased cellular excitability. These findings justify further work examining the potential role of MSK1 in other mechanisms of cell stress and neuroprotection, including ischemia and preconditioning. Finally, the elevated levels of cell death observed in *MSK1* null mice raise the prospect that approaches designed to enhance MSK1 activity could abrogate some of the pathophysiological effects associated with, and potentially underlying, the development of epilepsy.
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